LITB [LightInTheBox] CT ORDER: (Original Filing)
[]
NCTY [The9] F-3/A:
[] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Shanghai, China May 23, 2016 EX-23.1 2 d165215dex231.htm EX-23.1] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Shanghai, China May 23, 2016 EX-23.2 3 d165215dex232.htm EX-23.2]
SPIL [SILICONWARE PRECISION INDUSTRIES CO] 6-K: (Original Filing)
[Siliconware Precision Industries Co., Ltd. Press Release Issued on: 2016/5/23 The Company cautions its shareholders and others considering trading its securities that the special review committee has not formally reviewed or evaluated the Proposed Transaction. There can be no assurance that any definitive agreement will be executed in relation to the Proposed Transaction or that the Proposed Transaction or any]
IDI [IDI] 8-K: (Original Filing)
[May 23, 2016 IDI, Inc. Re: Common Stock registered under Registration Statement on Form S-3 Ladies and Gentlemen: We have acted as counsel to IDI, Inc., a Delaware corporation (the Company), in connection with the Securities Purchase Agreement dated May 17, 2016 (the Agreement) by and between the Company and Chardan Capital Markets, LLC, and the investors signatories thereto (the] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest Event Reported): May 23, 2016 IDI, Inc. Delaware 333-158336 77-0688094 _____________________ _____________ ______________ of incorporation) Identification No.) 2650 North Military Trail, Suite 300, Boca Raton, Florida 33431 _________________________________ ___________ 561-757-4000 Not Applicable Top of the Form Item 8.01 Other Events. Top of the Form]
SPIL [SILICONWARE PRECISION INDUSTRIES CO] 6-K: Siliconware Precision Industries Co., Ltd. Press Release Issued
[Siliconware Precision Industries Co., Ltd. Press Release Issued on: 2016/5/23 The Company cautions its shareholders and others considering trading its securities that the special review committee has not formally reviewed or evaluated the Proposed Transaction. There can be no assurance that any definitive agreement will be executed in relation to the Proposed Transaction or that the Proposed Transaction or any]
BSPM [Biostar Pharmaceuticals] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) ☒ March 31, 2016 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]
IDI [IDI] 8-K: May 23, 2016 IDI, Inc. Re: Common Stock
[May 23, 2016 IDI, Inc. Re: Common Stock registered under Registration Statement on Form S-3 Ladies and Gentlemen: We have acted as counsel to IDI, Inc., a Delaware corporation (the Company), in connection with the Securities Purchase Agreement dated May 17, 2016 (the Agreement) by and between the Company and Chardan Capital Markets, LLC, and the investors signatories thereto (the] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest Event Reported): May 23, 2016 IDI, Inc. Delaware 333-158336 77-0688094 _____________________ _____________ ______________ of incorporation) Identification No.) 2650 North Military Trail, Suite 300, Boca Raton, Florida 33431 _________________________________ ___________ 561-757-4000 Not Applicable Top of the Form Item 8.01 Other Events. Top of the Form]
BSPM [Biostar Pharmaceuticals] 10-Q: FORM 10-Q (Mark One) ☒ March 31, 2016
[FORM 10-Q (Mark One) ☒ March 31, 2016 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]
DHRM [Dehaier Medical Systems] 6-K: (Original Filing)
[Dehaier Medical Announces Receipt of the Nasdaq Notification Letter The letter further states that the Company has 60 calendar days (until July 18, 2016) to submit a plan to Nasdaq setting forth how the Company plans to regain compliance with the Rule. If the Company is unable to file the Form 20-F by July 18, 2016, then the Company intends] []
